Table 1 Demographics of the study cohort at baseline

Clinical characteristics

 Females^a

12 (92.3)

24 (92.3)

 > 0.999

 Age at baseline (years)^b

35.1 (7.9)

32.9 (8.1)

0.435

 Disease duration (weeks)^c

40.9 (11.9–105.0)

4.0 (1.0–23.0)

0.003

 CSF opening pressure (cmH₂O)^b

28.6 (7.9)

32.6 (6.1)

0.129

 BMI (kg/m²)^c

33.5 (31.8–39.3)

35.0 (30.4–38.1)

0.803

 IIH-WOP^a

1 (7.7)

4 (15.4)

n.a

Therapy

 Acetazolamide^a

10 (76.9)

25 (96.2)

0.099

  Median acetazolamide dosage (mg)^c

1,125 (500–1,625)

750 (500–1,000)

0.602

 Topiramate^a

1 (7.7)

1 (3.8)

n.a

  Topiramate dosage (mg)

100

25

n.a

 Furosemide^a

0 (0.0)

3 (11.5)

n.a

  Median furosemide dosage (mg)^c

n.a

40 (20–40)

n.a

 Ventriculoperitoneal shunt

1 (7.7)

0 (0.0)

n.a

Headache

 Headache present^a

12 (92.3)

15 (57.7)

0.034

 Monthly headache days^c

8 (3–14)

4.5 (0–12)

0.178

 Chronic headache^a

2 (15.4)

4 (15.4)

n.a

 Comorbid migraine^a

6 (46.2)

5 (19.2)

0.131

 Treatment with an anti-CGRP mAb^a

3 (23.1)

1 (3.8)

n.a

Ophthalmological findings

 Papilledema^a

8 (61.5)

21 (80.8)

0.253

 Frisén-Scale^d

1 (0–3)

1 (0–4)

0.353

 Visual acuity of worse eye (logMAR)^d

1.20 (0.10–1.25)

1.20 (0.10–1.60)

0.941

 Decreased visual acuity^a

2 (15.4)

2 (7.7)

0.589

 Visual field mean deviation of worse eye (dB)^c

–1.01 (–6.55, 0.02)

–3.24 (–6.97, –1.04)

0.230

 Abnormal visual field^a

4 (30.8)

17 (65.4)

0.087

 pRNFL thickness of worse eye (µm)^b

100.9 (38.8)

115.0 (34.7)

0.254

 GCL volume of worse eye (mm³)^c

1.02 (0.93–1.05)

1.05 (0.94–1.13)

0.504

 Presence of a bat sign^a

10 (76.9)

25 (96.2)

0.099

 Abnormal ONSD^a

9 (69.2)

17 (65.4)

0.601

 Marginal ONSD^a

2 (15.4)

7 (26.9)

  ONSD of worse eye (mm)^b

5.54 (1.17)

5.46 (0.81)

0.805